Systemic Tofacitinib in Alopecia Areata: A Single Center Retrospective Descriptive Cohort Study

This retrospective descriptive cohort study evaluated the use of systemic tofacitinib in 45 patients with alopecia areata at a single medical center. Over an average treatment duration of 30 months, 78% of patients experienced significant to moderate hair regrowth, as measured by the Severity of Alopecia Tool (SALT) score. Patients with a disease duration of less than 10 years and those younger than 16 years responded better to treatment. Discontinuation of tofacitinib led to hair loss, but regrowth occurred upon resuming treatment. The most common side effect was mild dyslipidemia, which did not require stopping the medication. The study concludes that tofacitinib is an effective and well-tolerated treatment for alopecia areata in both pediatric and adult patients, with proper supervision and follow-up.